Lanicemine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lanicemine
Accession Number
DB11889
Description

Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 198.269
Monoisotopic: 198.115698459
Chemical Formula
C13H14N2
Synonyms
Not Available
External IDs
  • AZD-6765
  • AZD6765

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of adverse effects can be increased when Lanicemine is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Lanicemine.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Lanicemine.
AclidiniumLanicemine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lanicemine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lanicemine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Lanicemine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lanicemine.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Lanicemine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lanicemine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Pyridines and derivatives / Benzene and substituted derivatives / Heteroaromatic compounds / Azacyclic compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organoheterocyclic compound / Primary aliphatic amine / Primary amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
9TMU325RK3
CAS number
153322-05-5
InChI Key
FWUQWDCOOWEXRY-ZDUSSCGKSA-N
InChI
InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1
IUPAC Name
(1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-amine
SMILES
N[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1

References

General References
Not Available
PubChem Compound
9794203
PubChem Substance
347828224
ChemSpider
7969970
ChEMBL
CHEMBL467084
ZINC
ZINC000000006163
Wikipedia
Lanicemine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDepression1
2CompletedTreatmentMajor Depressive Disorder (MDD)2
2CompletedTreatmentTreatment Resistant Major Depressive Disorder1
1Active Not RecruitingTreatmentDepression / Post Traumatic Stress Disorder (PTSD)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDepression1
1CompletedTreatmentHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers1
1WithdrawnNot AvailableHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.85 mg/mLALOGPS
logP1.88ALOGPS
logP1.98ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.91 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity60.83 m3·mol-1ChemAxon
Polarizability21.81 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:57 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates